Following a diagnosis of breast cancer, the most immediate challenges in patient
management are the determination of prognosis and identification of the most appropriate …

Non-coding RNAs (ncRNAs) are regulators of intracellular and intercellular signaling in
breast cancer. ncRNAs modulate intracellular signaling to control diverse cellular processes …

In the last years, mortality from breast cancer has declined in western countries as a
consequence of a more widespread screening resulting in earlier detection, as well as an …

Abstract miRNAs have emerged, in the last decade, as key players in the carcinogenic
process, with many candidates identified as playing important roles in many aspects of …

Background The efficacy of cisplatin-based chemotherapy in non-small-cell lung cancer is
limited by the acquired drug resistance. Identification the RNAs related to the cisplatin …

Introduction Breast cancer is a genetically and phenotypically complex disease. To
understand the role of miRNAs in this molecular complexity, we performed miRNA …

Endocrine therapies such as tamoxifen and aromatase inhibitors are the standard treatment
options for estrogen receptor-positive breast cancer patients. However, resistance to these …

MicroRNAs are dysregulated in breast cancer. Heterogeneous Nuclear Ribonucleoprotein
A2/B1 (HNRNPA2/B1) is a reader of the N (6)-methyladenosine (m6A) mark in primary …

The microRNA-26 family, including miR-26a, miR-26b, miR-1297 and miR-4465, is a group
of broadly conserved small RNAs with identical sequences at the seed region. The …

Although important advances in the management of breast cancer (BC) have been recently
accomplished, it still constitutes the leading cause of cancer death in women worldwide. BC …